GD2-SPECIFIC CAR-T CELLS CO-EXPRESSING THE IL15 MEMBRANE FORM EFFECTIVELY LYSE GD2-POSITIVE CELL TARGETS
Journal: Cardiometry
Year: 2022

Genetically modified T cells expressing chimeric receptors (CAR-T) have become an important tool for the treatment of the CD19+ hematological tumors. Due to a single-chain variable fragment of the antibody as a part of the CAR receptor, the cells acquire their specificity against selected tumorassociated antigens. The 3rd generation CAR also includes transmembrane, co-stimulatory domains, and tyrosine activation motifs derived from CD3z.